Why choose the Champions' TumorGraft3D 150 Model Screen?
A cost-effective, proprietary matrix-free 3D ex vivo tumor model platform featuring 150 low-passage, clinically relevant organoids from 13 cancer indications. These organoids are derived from our comprehensive tumor bank of fully-characterized Patient-Derived Xenograft (PDX) models.
150 Clinically Relevant Models
3D tumor models retaining the clinical heterogeneity of the patients
Proprietary Matrix-Free 3D Assay
A matrix free assay with indication specific media retaining key molecular characteristics
Cost-Effective Screening Platform
Designed to reduce costs by utilizing scalable cohorts instead of stand alone studies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and multiple endpoints
Champions' TumorGraft3D 150 Model Screen is an advanced platform showcasing 150 highly unique 3D tumor models
Champions' TumorGraft3D is an ex vivo drug screening platform featuring low-passage, 3D tumor models established from our clinically annotated proprietary collection of primary PDX models. These organoids replicate the complex cellular heterogeneity and tumor microenvironment of cancer, providing a more accurate model of patient-specific tumor biology in a 3D cellular environment.
Industry's largest available screen with 150 models representing 13 tumor indications, the assay uses a proprietary matrix-free, indication-specific media to enable 3D organoid formation while preserving key molecular and phenotypic features of patient tumors, including critical mutations like KRAS, kinases, and epigenetic targets.
TumorGraft3D’s molecular characterization, clinical relevance, and versatility make it the ideal ex vivo model for:
- Assessing agent efficacy and on-target effects.
- Unraveling tumor biology and interactions within the tumor microenvironment.
- Evaluating synergistic drug combinations for more informed data-driven drug development decisions.
Champions' elite TumorGraft3D 150 Model Screen offers:
-
Thoroughly characterized organoids with with detailed patient response data, clinical annotations, proliferation metrics, and responses to standard-of-care (SOC) treatments available.
-
Assay ranks test agents across multiple models, study tumor cell biology and microenvironment interactions, and evaluates therapeutic synergy in combination treatments.
-
Expanded Analysis Opportunities: DRUG-seq and Luminex endpoint analyses are available for additional evaluation, offering deeper understanding at an extra cost.
-
Tailored Bioinformatics Solutions: We offer custom bioinformatics analysis and NGS data licensing upon request, ensuring personalized insights to meet your specific research needs.
-
Cost-Effective Solution: Our services are designed to save costs compared to standalone studies, offering a budget-friendly yet comprehensive approach to your research objectives.
-
50% off of a Standard of Care agent arm (selected by Champions) and an option to select cohorts of 25, 50, 100, or 150 preselected models.
TumorGraft3D 150 Model Screen: Assay Workflow
.png?width=1172&height=255&name=Copy%20of%20TumorGraft3D%20workflow%20(1).png "Copy of TumorGraft3D workflow (1)")
TumorGraft3D Model Cohorts at a Glance
-
Activated CDK4/6 Signaling Models
Test your novel inhibitor alone or in combination with SoC therapies and explore mechanisms of drug action. -
In Vivo Vemurafenib Resistant Melanoma Models
Screen new BRAFi and broad TKi to overcome acquired resistance and validate drug target. -
ARv7 Prostate Cancer Models
Investigate your therapeutics in aggressive models resistant to enzalutamide and abiraterone. -
RETamp Models
Explore therapies against this novel targetable molecular alteration in solid tumors. -
In Vivo Olaparib Resistant Models
Test innovative ways to inhibit PARP activity and/or target the DNA-repair process.
-
Platinum R/R Models
Explore new ways to overcome resistance to first-line chemotherapy. -
BRCAmut Breast & Ovarian Cancer Models
Screen your therapeutics in familial breast and ovarian cancer. -
PIK3CAmut & PTEN-Aberrant Breast Cancer Models
Investigate novel therapeutics for targetable genetic aberrations in invasive breast cancer. -
Castration-Resistant Prostate Cancer (CRPC)
Explore novel approaches for prostate cancer relapsed after ADT. -
In Vivo Trastuzumab Resistant Gastric Cancer Models
Investigate novel approaches for HER2 inhibition with single agent and/or combination therapies.
Exemplary TumorGraft3D Screen Drug Responses
